Arndt Vogel
809 works · 38,871 citations · h-index 84
Top works
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
- Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
- Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- NASH limits anti-tumour surveillance in immunotherapy-treated HCC
- Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
- A comparison of fibrosis progression in chronic liver diseases
- Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
- Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients
- SO-5 Futibatinib in patients with FGFR2-rearranged intrahepatic cholangiocarcinoma: Responder analyses of efficacy and safety from the phase 2 FOENIX-CCA2 study
- Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines
- Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
- Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score
- Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management
- Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma